FOLR2

Folate receptor beta

3,954 patent compounds predicted against FOLR2, 3,331 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1604607	0.78	13/20
SCHEMBL1604476	0.73	13/20
SCHEMBL1604480	0.73	13/20
SCHEMBL1604603	0.72	13/20
SCHEMBL1604705	0.72	13/20
SCHEMBL1604546	0.58	13/20
SCHEMBL3156359	0.57	13/20
SCHEMBL1604542	0.55	13/20
SCHEMBL1604735	0.55	13/20
SCHEMBL1604731	0.52	13/20
SCHEMBL1603722	1.00	12/20
SCHEMBL1603726	1.00	12/20
SCHEMBL1604573	1.00	12/20
SCHEMBL1604578	1.00	12/20
SCHEMBL1605429	1.00	12/20
SCHEMBL1605437	1.00	12/20
SCHEMBL1603940	0.97	12/20
SCHEMBL1603944	0.97	12/20
SCHEMBL1604402	0.79	12/20
SCHEMBL1605463	0.78	12/20

Germline variants in FOLR2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full FOLR2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to FOLR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer	PHASE3	ACTIVE_NOT_RECRUITING
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression	PHASE3	COMPLETED
How Precision Diets, Through Gut Bacteria, Affect Anemia in Nepalese Adolescent	PHASE3	NOT_YET_RECRUITING
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.	PHASE2	RECRUITING
A Placebo-controlled Trial of Folinic Acid in Children With ASD	PHASE2	RECRUITING
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma	PHASE2	COMPLETED
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma	PHASE2	COMPLETED
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer	PHASE2	RECRUITING
Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer	PHASE2	COMPLETED
Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)	PHASE2	COMPLETED
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer	PHASE2	RECRUITING
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer	PHASE2	COMPLETED
Intraoperative Imaging of Pulmonary Nodules by OTL38	PHASE1	COMPLETED
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging	PHASE1	COMPLETED
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors	PHASE1	COMPLETED
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers	PHASE1	COMPLETED
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors	PHASE1	COMPLETED
Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)	PHASE1	WITHDRAWN
Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer	PHASE1	COMPLETED
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML	PHASE1	WITHDRAWN
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen	nan	UNKNOWN
Measurement of the Folate Receptor in Blood	nan	COMPLETED
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer	nan	UNKNOWN
DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization	nan	COMPLETED
Influence of Iron and Foliate Transporters on Bioavailability of These Micronutrients in the Organism	nan	COMPLETED
Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies	nan	RECRUITING
Assessing Colonic Folate Absorption & Metabolism	nan	UNKNOWN
INAS-FOCUS (International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study)	nan	COMPLETED
Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a FOLR2 binder may also engage these)

Protein	Name	Similarity
P35846	—	1.000	P35846 →
Q05685	—	1.000	Q05685 →
P41439	—	1.000	P41439 →
P02702	—	0.998	P02702 →
FOLR1	Folate receptor alpha	0.996	landscape →
F1M928	—	0.992	F1M928 →
A6ND01	—	0.989	A6ND01 →
P02752	—	0.987	P02752 →
Q9EQF4	—	0.986	Q9EQF4 →
P86009	—	0.978	P86009 →
Q5T197	—	0.978	Q5T197 →
A2A863	—	0.977	A2A863 →
Q9TTK6	—	0.976	Q9TTK6 →
O70423	—	0.975	O70423 →
Q9R1Q9	—	0.975	Q9R1Q9 →
Q5XHC5	—	0.974	Q5XHC5 →
Q9NQ34	—	0.974	Q9NQ34 →
Q8JZQ5	—	0.974	Q8JZQ5 →
Q3U435	—	0.974	Q3U435 →
Q9DBX3	—	0.973	Q9DBX3 →
Q8N158	—	0.973	Q8N158 →
PRF1	Perforin-1	0.973	landscape →
P26011	—	0.973	P26011 →
O19071	—	0.973	O19071 →
Q3V5L5	—	0.973	Q3V5L5 →
A1L314	—	0.973	A1L314 →
A6QQ07	—	0.973	A6QQ07 →
PIGS	GPI-anchor transamidase component PIGS	0.972	landscape →
Q9UK23	—	0.972	Q9UK23 →
F1QCC6	—	0.972	F1QCC6 →